NASDAQ:MBIO

Mustang Bio Competitors

$3.05
-0.12 (-3.79 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.98
Now: $3.05
$3.16
50-Day Range
$3.02
MA: $3.35
$3.73
52-Week Range
$2.42
Now: $3.05
$5.22
Volume1.60 million shs
Average Volume2.88 million shs
Market Capitalization$259.78 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85

Competitors

Mustang Bio (NASDAQ:MBIO) Vs. TRIL, ENTA, PRTA, RYTM, PAHC, and GTHX

Should you be buying MBIO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Mustang Bio, including Trillium Therapeutics (TRIL), Enanta Pharmaceuticals (ENTA), Prothena (PRTA), Rhythm Pharmaceuticals (RYTM), Phibro Animal Health (PAHC), and G1 Therapeutics (GTHX).

Mustang Bio (NASDAQ:MBIO) and Trillium Therapeutics (NASDAQ:TRIL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Risk & Volatility

Mustang Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Trillium Therapeutics has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500.

Insider and Institutional Ownership

25.8% of Mustang Bio shares are held by institutional investors. Comparatively, 67.5% of Trillium Therapeutics shares are held by institutional investors. 3.4% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Mustang Bio and Trillium Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mustang BioN/A-90.84%-68.47%
Trillium TherapeuticsN/A-70.00%-28.84%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Mustang Bio and Trillium Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mustang Bio00403.00
Trillium Therapeutics01602.86

Mustang Bio currently has a consensus target price of $11.00, indicating a potential upside of 260.66%. Trillium Therapeutics has a consensus target price of $21.8333, indicating a potential upside of 118.77%. Given Mustang Bio's stronger consensus rating and higher possible upside, analysts clearly believe Mustang Bio is more favorable than Trillium Therapeutics.

Earnings and Valuation

This table compares Mustang Bio and Trillium Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mustang BioN/AN/A$-46,390,000.00($1.29)-2.36
Trillium Therapeutics$120,000.008,567.91$-41,620,000.00($1.38)-7.23

Trillium Therapeutics has higher revenue and earnings than Mustang Bio. Trillium Therapeutics is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Trillium Therapeutics beats Mustang Bio on 7 of the 12 factors compared between the two stocks.

Enanta Pharmaceuticals (NASDAQ:ENTA) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.

Analyst Recommendations

This is a summary of recent recommendations for Enanta Pharmaceuticals and Mustang Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Enanta Pharmaceuticals13302.29
Mustang Bio00403.00

Enanta Pharmaceuticals currently has a consensus price target of $65.2857, suggesting a potential upside of 28.82%. Mustang Bio has a consensus price target of $11.00, suggesting a potential upside of 260.66%. Given Mustang Bio's stronger consensus rating and higher probable upside, analysts clearly believe Mustang Bio is more favorable than Enanta Pharmaceuticals.

Profitability

This table compares Enanta Pharmaceuticals and Mustang Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Enanta Pharmaceuticals-29.53%-3.75%-3.53%
Mustang BioN/A-90.84%-68.47%

Insider & Institutional Ownership

90.8% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 25.8% of Mustang Bio shares are owned by institutional investors. 10.9% of Enanta Pharmaceuticals shares are owned by company insiders. Comparatively, 3.4% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk and Volatility

Enanta Pharmaceuticals has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Earnings & Valuation

This table compares Enanta Pharmaceuticals and Mustang Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enanta Pharmaceuticals$122.47 million8.35$-36,170,000.00($0.89)-56.94
Mustang BioN/AN/A$-46,390,000.00($1.29)-2.36

Enanta Pharmaceuticals has higher revenue and earnings than Mustang Bio. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Enanta Pharmaceuticals beats Mustang Bio on 7 of the 13 factors compared between the two stocks.

Prothena (NASDAQ:PRTA) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability and valuation.

Earnings & Valuation

This table compares Prothena and Mustang Bio's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,227.34$-77,680,000.00($1.95)-12.74
Mustang BioN/AN/A$-46,390,000.00($1.29)-2.36

Mustang Bio has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Prothena and Mustang Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
Mustang BioN/A-90.84%-68.47%

Institutional and Insider Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 25.8% of Mustang Bio shares are owned by institutional investors. 30.4% of Prothena shares are owned by company insiders. Comparatively, 3.4% of Mustang Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility & Risk

Prothena has a beta of 1.71, suggesting that its stock price is 71% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Prothena and Mustang Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Mustang Bio00403.00

Prothena currently has a consensus target price of $29.4286, indicating a potential upside of 18.42%. Mustang Bio has a consensus target price of $11.00, indicating a potential upside of 260.66%. Given Mustang Bio's higher probable upside, analysts plainly believe Mustang Bio is more favorable than Prothena.

Mustang Bio (NASDAQ:MBIO) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, dividends, analyst recommendations and risk.

Volatility & Risk

Mustang Bio has a beta of 1.85, indicating that its share price is 85% more volatile than the S&P 500. Comparatively, Rhythm Pharmaceuticals has a beta of 1.57, indicating that its share price is 57% more volatile than the S&P 500.

Valuation and Earnings

This table compares Mustang Bio and Rhythm Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mustang BioN/AN/A$-46,390,000.00($1.29)-2.36
Rhythm PharmaceuticalsN/AN/A$-140,730,000.00($3.86)-5.11

Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mustang Bio and Rhythm Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Mustang BioN/A-90.84%-68.47%
Rhythm PharmaceuticalsN/A-55.21%-50.73%

Analyst Recommendations

This is a breakdown of recent ratings for Mustang Bio and Rhythm Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Mustang Bio00403.00
Rhythm Pharmaceuticals01502.83

Mustang Bio currently has a consensus target price of $11.00, indicating a potential upside of 260.66%. Rhythm Pharmaceuticals has a consensus target price of $50.6667, indicating a potential upside of 157.06%. Given Mustang Bio's stronger consensus rating and higher probable upside, analysts plainly believe Mustang Bio is more favorable than Rhythm Pharmaceuticals.

Institutional and Insider Ownership

25.8% of Mustang Bio shares are held by institutional investors. Comparatively, 88.4% of Rhythm Pharmaceuticals shares are held by institutional investors. 3.4% of Mustang Bio shares are held by company insiders. Comparatively, 9.5% of Rhythm Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Mustang Bio beats Rhythm Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

Phibro Animal Health (NASDAQ:PAHC) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Volatility and Risk

Phibro Animal Health has a beta of 0.46, indicating that its stock price is 54% less volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Insider and Institutional Ownership

50.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 25.8% of Mustang Bio shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by insiders. Comparatively, 3.4% of Mustang Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Phibro Animal Health and Mustang Bio's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Phibro Animal Health$800.40 million1.23$33.55 million$1.0822.62
Mustang BioN/AN/A$-46,390,000.00($1.29)-2.36

Phibro Animal Health has higher revenue and earnings than Mustang Bio. Mustang Bio is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Phibro Animal Health and Mustang Bio, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Phibro Animal Health11001.50
Mustang Bio00403.00

Phibro Animal Health presently has a consensus target price of $21.50, suggesting a potential downside of 11.99%. Mustang Bio has a consensus target price of $11.00, suggesting a potential upside of 260.66%. Given Mustang Bio's stronger consensus rating and higher probable upside, analysts clearly believe Mustang Bio is more favorable than Phibro Animal Health.

Profitability

This table compares Phibro Animal Health and Mustang Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Phibro Animal Health5.37%23.70%5.99%
Mustang BioN/A-90.84%-68.47%

Summary

Phibro Animal Health beats Mustang Bio on 9 of the 13 factors compared between the two stocks.

G1 Therapeutics (NASDAQ:GTHX) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Risk and Volatility

G1 Therapeutics has a beta of 2.44, indicating that its stock price is 144% more volatile than the S&P 500. Comparatively, Mustang Bio has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500.

Insider & Institutional Ownership

77.9% of G1 Therapeutics shares are owned by institutional investors. Comparatively, 25.8% of Mustang Bio shares are owned by institutional investors. 14.5% of G1 Therapeutics shares are owned by insiders. Comparatively, 3.4% of Mustang Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for G1 Therapeutics and Mustang Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
G1 Therapeutics00703.00
Mustang Bio00403.00

G1 Therapeutics presently has a consensus price target of $49.1667, indicating a potential upside of 109.13%. Mustang Bio has a consensus price target of $11.00, indicating a potential upside of 260.66%. Given Mustang Bio's higher possible upside, analysts clearly believe Mustang Bio is more favorable than G1 Therapeutics.

Valuation and Earnings

This table compares G1 Therapeutics and Mustang Bio's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
G1 TherapeuticsN/AN/A$-122,450,000.00($3.27)-7.19
Mustang BioN/AN/A$-46,390,000.00($1.29)-2.36

G1 Therapeutics is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares G1 Therapeutics and Mustang Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
G1 TherapeuticsN/A-49.35%-41.53%
Mustang BioN/A-90.84%-68.47%

Summary

G1 Therapeutics beats Mustang Bio on 6 of the 10 factors compared between the two stocks.


Mustang Bio Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.98-4.0%$1.03 billion$120,000.00-3.70Analyst Report
News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$50.68-2.1%$1.02 billion$122.47 million-27.85Analyst Downgrade
News Coverage
Prothena logo
PRTA
Prothena
2.1$24.85-3.2%$994.15 million$810,000.00-9.71Increase in Short Interest
News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$19.71-5.2%$989.07 millionN/A-6.48Increase in Short Interest
News Coverage
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.43-1.1%$988.27 million$800.40 million23.05
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$23.51-6.8%$986.46 millionN/A-8.11Insider Selling
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$20.41-2.8%$984.50 million$1.52 million-10.86Increase in Short Interest
News Coverage
Gap Down
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.34-1.0%$950.61 millionN/A-12.60
Radius Health logo
RDUS
Radius Health
1.1$19.71-0.2%$924.28 million$173.32 million-8.08
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.67-0.7%$914.90 million$227.19 million46.31Analyst Upgrade
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.45-0.5%$897.94 millionN/A0.00
Annexon logo
ANNX
Annexon
1.9$23.42-2.2%$893.66 millionN/A0.00Increase in Short Interest
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.95-0.1%$858.83 millionN/A-10.37Analyst Report
News Coverage
Merus logo
MRUS
Merus
1.6$22.52-1.7%$858.62 million$31.13 million-7.34Analyst Report
Ardelyx logo
ARDX
Ardelyx
1.6$8.69-0.3%$857.53 million$5.28 million-8.60High Trading Volume
Unusual Options Activity
News Coverage
Affimed logo
AFMD
Affimed
1.6$9.51-0.3%$839.98 million$23.96 million-16.12Earnings Announcement
Analyst Revision
News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.82-5.4%$838.42 millionN/A-22.98
Epizyme logo
EPZM
Epizyme
1.8$8.10-1.6%$824.46 million$23.80 million-3.63
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.30-0.3%$820.59 million$322.36 million123.57
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.27-0.8%$819.20 million$296.70 million47.49Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$14.73-5.6%$787.79 millionN/A0.00Increase in Short Interest
Gap Down
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.33-2.7%$782.70 millionN/A0.00Increase in Short Interest
Gap Down
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.02-0.1%$755.02 million$148.36 million-7.02Analyst Revision
News Coverage
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$5.05-3.2%$728.99 million$322.07 million-4.81Decrease in Short Interest
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.71-0.2%$728.84 million$40.89 million-3.35
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.33-2.7%$716.63 million$150,000.00-4.76
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$19.63-1.9%$702.93 million$6.83 million-20.24
Chimerix logo
CMRX
Chimerix
1.3$8.18-1.6%$700.85 million$12.52 million-14.35Analyst Upgrade
Increase in Short Interest
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.71-7.0%$688.35 million$2.22 million-15.94Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.45-1.8%$680 million$13.80 million-14.23
Veru logo
VERU
Veru
1.4$9.42-1.8%$677.41 million$42.59 million-33.64Analyst Report
Analyst Revision
News Coverage
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.4$15.90-4.2%$673.79 million$17.26 million-4.42Analyst Revision
News Coverage
Kadmon logo
KDMN
Kadmon
1.8$3.92-0.5%$673.52 million$5.09 million-6.53Analyst Downgrade
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.88-1.2%$671.22 million$19.56 million-19.34News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.28-1.3%$669.56 million$252 million-2.07High Trading Volume
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$8.49-4.2%$641.23 millionN/A-2.38Analyst Downgrade
Increase in Short Interest
News Coverage
Gap Down
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.98-2.0%$625.09 million$143.01 million-1.14
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$32.60-1.0%$623.12 million$9.64 million-5.31
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$11.56-0.0%$616.55 millionN/A-4.64Analyst Revision
News Coverage
Gap Down
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.58-5.6%$609.03 million$59.29 million-23.87Increase in Short Interest
Gap Down
IDEAYA Biosciences logo
IDYA
IDEAYA Biosciences
1.5$18.61-0.5%$600.36 millionN/A-9.90Analyst Report
High Trading Volume
News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.5$21.72-1.6%$594.39 million$8 million-8.01News Coverage
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$24.45-3.1%$594.33 million$12.69 million-11.75Increase in Short Interest
Gap Down
OrganiGram logo
OGI
OrganiGram
1.6$2.52-1.6%$585.32 million$64.61 million-3.71Earnings Announcement
Analyst Report
Decrease in Short Interest
Analyst Revision
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.2$44.27-0.1%$585.12 million$195.89 million126.49News Coverage
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$34.69-4.9%$580.95 millionN/A-16.06
Mirum Pharmaceuticals logo
MIRM
Mirum Pharmaceuticals
1.8$18.44-0.7%$560.95 millionN/A-5.36
SIGA Technologies logo
SIGA
SIGA Technologies
0.3$7.26-1.5%$557.19 million$26.74 million18.15
Crinetics Pharmaceuticals logo
CRNX
Crinetics Pharmaceuticals
1.8$16.73-3.5%$552.58 million$1.19 million-6.97
IVERIC bio logo
ISEE
IVERIC bio
1.5$5.95-3.7%$536.51 millionN/A-4.72News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.